Format

Send to

Choose Destination
Ann Endocrinol (Paris). 2014 Sep;75(4):232-40. doi: 10.1016/j.ando.2014.06.004. Epub 2014 Aug 22.

The clinical significance of somatostatin in pancreatic diseases.

Author information

1
Department of biomedical and environmental analysis, Wrocław Medical University, 211 Borowska, Poland. Electronic address: mariola.sliwinska-mosson@umed.wroc.pl.
2
Department of biomedical and environmental analysis, Wrocław Medical University, 211 Borowska, Poland.

Abstract

The aim of the study was to provide knowledge on somatostatin and its action on the body, particularly the pancreas - in physiological and pathological conditions. In order to get to know the properties of somatostatin, a hormone discovered over forty years ago, many studies that define its structure and the mechanisms by which it operates have been conducted. The properties of somatostatin receptors and the effect of somatostatin on the body - both a healthy one and in various disease stages - were determined. It was proven that the somatostatin had an inhibitive effect on the endo- and exocrine secretion of this organ, which allowed a hypothesis that it might play an important role in the pathophysiology of diabetes. In patients with severe acute pancreatitis, both somatostatin and octreotide appear to reduce the mortality rate significantly, without any effect on the incidence of complications. Nevertheless, somatostatin analogues may be the cause of acute pancreatitis. With regard to severe chronic pancreatitis, refractory to other forms of therapy, it was demonstrated that octreotide significantly alleviated pain in many patients. A similar risk of death, and generally a lower risk of complications were found in the group of somatostatin-treated patients with chronic pancreatitis when compared to those receiving placebo or untreated. The occurrence of hyperglycemia after the application of somatostatin analogues, and in particular after pasireotide, is disturbing. Somatostatin analogues have found application in the treatment of cancers. They may improve symptoms in patients with gastroenteropancreatic neuroendocrine tumors (NETs) and stabilize the tumor growth (PROMID study). However, the optimal hormone dose sizes and frequencies necessary to ensure a full therapeutic effect in selected diseases of the pancreas have not been completely determined.

KEYWORDS:

Acute pancreatitis; Cancer du système endocrinien; Chronic pancreatitis; Diabetes; Diabète; Endocrine cancer; Pancréatite aiguë; Pancréatite chronique; Somatostatin; Somatostatine

PMID:
25156131
DOI:
10.1016/j.ando.2014.06.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Masson (France)
Loading ...
Support Center